Outcome measures
bleeding, septic arthritis, osteoarthritis, pain, acute pseudo-septic
OSTEOARTHRITIS, BLEEDING, SEPTIC ARTHRITIS, ADVERSE EVENT
Patients were assessed for the pain by visual analog scale (pVAS:0–10), global visual analog scale (gVAS:0–10), modified Thai version of the Western Ontario and McMaster osteoarthritis index (WOMAC) pain subscale range, 0 [no pain]-10 [extreme pain], the stiffness subscale range, 0 [no stiffness]-10 [extreme stiffness], the joint usage subscale range, 0 [excellent]-10 [unable] [Acetaminophen at the maximum dose of 3 g per day with a 12-h washout before each follow-up visit was offered as a rescue for pain. The numbers of a 500 mg of acetaminophen tablet used were recorded at each visit. NSAIDs and oral glucocorticoid were not allowed during the study. Adverse events were recorded from screening to the end of the study. Injection site pain, acute pseudo-septic or septic arthritis and bleeding were recorded at the baseline visit.During the COVID-19 pandemic, if patients were not able to come to the hospital, questionnaires were sent to patients and returned to the researchers by postal or electronic mails. At baseline visit, patients and their caregivers were instructed by the research assistant and a standard short video how to perform a chair stand test and record a 20-m walk time.